I am a
Home I AM A Search Login

Papers of the Week


Papers: 3 Sep 2022 - 9 Sep 2022


Pharmacology/Drug Development


2022 Sep 06


J Headache Pain


23


1

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.

Authors

Cowan RP, Marmura MJ, Diener H-C, Starling AJ, Schim J, Hirman J, Brevig T, Cady R
J Headache Pain. 2022 Sep 06; 23(1):115.
PMID: 36068494.

Abstract

Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationships between headache frequency reductions and changes in AHM use in patients in PROMISE-2.